Progesterone-receptor positive breast cancer
diseaseOn this page
Summary
Progesterone-receptor positive breast cancer (MONDO:0000615) is a cancer and 21 clinical trials. Top therapeutic interventions include vinorelbine tartrate, aldesleukin, and anastrozole. A subtype of breast carcinoma by gene expression profile — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 21
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | progesterone-receptor positive breast cancer |
| Mondo ID | MONDO:0000615 |
| DOID | DOID:0060077 |
| UMLS | C4733094 |
| MedGen | 1843473 |
| Is cancer (heuristic) | yes |
Disease family
This is a subtype of breast carcinoma by gene expression profile. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › breast carcinoma › breast carcinoma by gene expression profile › progesterone-receptor positive breast cancer
Related subtypes (7): progesterone-receptor negative breast cancer, Her2-receptor negative breast cancer, breast tumor luminal A or B, HER2 positive breast carcinoma, normal breast-like subtype of breast carcinoma, estrogen-receptor positive breast cancer, estrogen-receptor negative breast cancer
Subtypes (2): triple-positive breast carcinoma, hormone receptor-positive breast cancer
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 12 |
| PHASE1 | 6 |
| Not specified | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00003199 | PHASE2 | COMPLETED | Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer |
| NCT00057941 | PHASE2 | COMPLETED | Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer |
| NCT00194779 | PHASE2 | COMPLETED | Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery |
| NCT00194792 | PHASE2 | TERMINATED | Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer |
| NCT00602043 | PHASE2 | COMPLETED | F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer |
| NCT01037790 | PHASE2 | COMPLETED | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
| NCT01100489 | PHASE2 | WITHDRAWN | Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer |
| NCT01194440 | PHASE2 | COMPLETED | Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms |
| NCT02015559 | PHASE2 | COMPLETED | Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus |
| NCT02269670 | PHASE2 | TERMINATED | Phase II Study of Everolimus Beyond Progression |
| NCT02273752 | PHASE2 | TERMINATED | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer |
| NCT04504916 | PHASE2 | TERMINATED | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) |
| NCT01791478 | PHASE1 | ACTIVE_NOT_RECRUITING | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer |
| NCT05868226 | PHASE1 | RECRUITING | PRE-I-SPY Phase I/Ib Oncology Platform Program |
| NCT06586957 | PHASE1 | RECRUITING | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors |
| NCT01208441 | PHASE1 | TERMINATED | RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer |
| NCT04602117 | PHASE1 | WITHDRAWN | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer |
| NCT06264921 | PHASE1 | TERMINATED | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors |
| NCT01824836 | Not specified | ACTIVE_NOT_RECRUITING | A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) |
| NCT01409811 | Not specified | TERMINATED | Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid |
| NCT02186470 | Not specified | COMPLETED | Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| VINORELBINE TARTRATE | 4 | 2 |
| ALDESLEUKIN | 4 | 1 |
| ANASTROZOLE | 4 | 1 |
| BUSULFAN | 4 | 1 |
| EXEMESTANE | 4 | 1 |
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| FLUOROESTRADIOL F-18 | 4 | 1 |
| FULVESTRANT | 4 | 1 |
| GEFITINIB | 4 | 1 |
| MEGESTROL ACETATE | 4 | 1 |
| PALBOCICLIB | 4 | 1 |
| SARGRAMOSTIM | 4 | 1 |
| THIOTEPA | 4 | 1 |
| TRASTUZUMAB DERUXTECAN | 4 | 1 |
| TRIPTORELIN PAMOATE | 4 | 1 |
| TUCATINIB | 4 | 1 |
| ZANIDATAMAB | 4 | 1 |
| CIRMTUZUMAB | 3 | 1 |
| EVORPACEPT | 2 | 1 |
| VEDOTIN | 2 | 1 |
| CHEMBL5402818 | 0 | 1 |
| CHEMBL4068871 | 0 | 1 |
| CHEMBL4567541 | 0 | 1 |